CompletedNCT03367533
Perampanel and Ketamine for Treatment-Resistant Depression: A Pilot Study
About this title
Read the official source — NCT03367533Medication studyAges 18–65United StatesPTSD
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: November 29, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 13
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03367533
- Official title
Show the full official title
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedNew Haven
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Did this study involve medication?
Yes. The study involved medication, including ketamine, Perampanel and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
